Search results for " Pregnancy complications"

showing 10 items of 330 documents

Dysregulated genes and their functional pathways in luteinized granulosa cells from PCOS patients after cabergoline treatment

2018

Polycystic ovarian syndrome (PCOS) is a common reproductive disorder frequently associated with a substantial risk factor for ovarian hyperstimulation syndrome (OHSS). Dopamine receptor 2 (D2) agonists, like cabergoline (Cb2), have been used to reduce the OHSS risk. However, lutein granulosa cells (LGCs) from PCOS patients treated with Cb2 still show a deregulated dopaminergic tone (decreased D2 expression and low dopamine production) and increased vascularization compared to non-PCOS LGCs. Therefore, to understand the PCOS ovarian physiology, it is important to explore the mechanisms that underlie syndrome based on the therapeutic effects of Cb2. Here, LGCs from non-PCOS and PCOS patients …

0301 basic medicineAdultEmbryologymedicine.medical_specialtyendocrine systemCabergolineendocrine system diseasesOvarian hyperstimulation syndromeAKT103 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineCabergolineLuteal CellsmedicineHumansErgolines030219 obstetrics & reproductive medicineGranulosa Cellsbusiness.industryDopaminergicOvaryObstetrics and Gynecologynutritional and metabolic diseasesCell Biologymedicine.diseasefemale genital diseases and pregnancy complicationsVascular endothelial growth factorVascular endothelial growth factor A030104 developmental biologyEndocrinologyReproductive MedicinechemistryGene Expression RegulationDopamine receptorDopaminergic synapseCase-Control StudiesDopamine AgonistsFemalebusinessTranscriptomeBiomarkersmedicine.drugPolycystic Ovary Syndrome
researchProduct

A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers

2018

Single nucleotide polymorphisms (SNPs) in DNA glycosylase genes involved in the base excision repair (BER) pathway can modify breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We previously found that SNP rs34259 in the uracil-DNA glycosylase gene (UNG) might decrease ovarian cancer risk in BRCA2 mutation carriers. In the present study, we validated this finding in a larger series of familial breast and ovarian cancer patients to gain insights into how this UNG variant exerts its protective effect. We found that rs34259 is associated with significant UNG downregulation and with lower levels of DNA damage at telomeres. In addition, we found that this SNP is associated with…

0301 basic medicineCancer Researchmedicine.medical_specialtyendocrine system diseasesUracil-DNA glycosylaseEuropean Regional Development Fundlcsh:RC254-282Polymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineBRCA2 MutationRisk FactorsPolitical scienceHealthy volunteersGeneticsmedicineHumansSNPGenetic Predisposition to DiseaseUracil-DNA Glycosidaseskin and connective tissue diseasesResearch ArticlesBRCA2 ProteinOvarian NeoplasmsNetwork onOxidative stress susceptibilityGeneral MedicineMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseBRCA2female genital diseases and pregnancy complicationsuracil‐DNA glycosylase030104 developmental biologyCancer risk modifierOncology030220 oncology & carcinogenesisFamily medicineMutationMolecular MedicineDNA damageFemaleChristian ministryTelomere damageOvarian cancerHuman cancerResearch Article
researchProduct

Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia

2020

Abstract Non-classical congenital adrenal hyperplasia (NC-CAH) includes a group of genetic disorders due to a broad class of CYP21A2 variants identifying a disease-causing ‘C’ genotype. The heterozygous carriers of CYP21 mutations are at increased risk of developing clinically evident hyperandrogenism, even though clinical and laboratory characteristics are still underestimated. With the aim of obtaining a more accurate delineation of the phenotype of heterozygous carrier of CAH, we analyzed clinical, biochemical and molecular characteristics in a cohort of Sicilian subjects. Fifty-seven females with biallelic and monoallelic CYP21A2 variants classifying NC-CAH (24) and heterozygous carrier…

0301 basic medicineHirsutismHydrocortisoneendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryPhysiologyOverweighturologic and male genital diseasesBiochemistrySettore MED/13 - Endocrinologia0302 clinical medicineEndocrinologySettore BIO/10 - BiochimicaGenotypeMedicineChildhirsutismPolycystic ovaryfemale genital diseases and pregnancy complications030220 oncology & carcinogenesisCohortMolecular MedicineFemalemedicine.symptomAdultHeterozygotecongenital hereditary and neonatal diseases and abnormalitiesAdolescentYoung Adult03 medical and health sciencesHumansCongenital adrenal hyperplasiaMolecular BiologyHeterozygous carrierAdrenal Hyperplasia Congenitalbusiness.industryHyperandrogenismCongenital adrenal hyperplasianutritional and metabolic diseasesHeterozygote advantageCell BiologyOverweightmedicine.diseaseOligomenorrhea17OHProgesterone deficiency030104 developmental biologyMutationSteroid 21-HydroxylaseHyperandrogenismbusinessThe Journal of Steroid Biochemistry and Molecular Biology
researchProduct

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

2016

High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10–0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who …

0301 basic medicineOncologyAdultmedicine.medical_specialtyBevacizumabendocrine system diseasesPrognosimedicine.medical_treatmentHigh-grade serous ovarian carcinoma (HGSOC)Gene ExpressionAntineoplastic AgentsKaplan-Meier EstimateBrief Communication03 medical and health sciences0302 clinical medicineOvarian carcinomaInternal medicineObstetrics and GynaecologyMedicineHumansPlatinumAgedAurora Kinase ANeoplasm StagingGynecologyAged 80 and overOvarian NeoplasmsChemotherapyAURKAbusiness.industryObstetrics and GynecologyRetrospective cohort studyMiddle AgedPrognosisImmunohistochemistryfemale genital diseases and pregnancy complicationsCystadenocarcinoma SerousClinical trialSerous fluid030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleAurora Kinase APersonalized medicineTherapybusinessmedicine.drugJournal of Ovarian Research
researchProduct

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer

2021

The aim of the study was to analyze the frequency and magnitude of association of 21 recurrent founder germline mutations in BRCA1, BRCA2, PALB2, RAD51C, and CHEK2 genes with ovarian cancer risk among unselected patients in Poland. We genotyped 21 recurrent germline mutations in BRCA1 (9 mutations), BRCA2 (4 mutations), RAD51C (3 mutations), PALB2 (2 mutations), and CHEK2 (3 mutations) among 2270 Polish ovarian cancer patients and 1743 healthy controls, and assessed the odds ratios (OR) for developing ovarian cancer for each gene. Mutations were detected in 369 out of 2095 (17.6%) unselected ovarian cancer cases and 117 out of 1743 (6.7%) unaffected controls. The ovarian cancer risk was ass…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesovarian cancer; recurrent mutations; BRCA1; BRCA2; RAD51C; PALB2; CHEK2; cancer riskPALB2<i>CHEK2</i>cancer riskBrca1 brca2lcsh:RC254-282Article03 medical and health sciences0302 clinical medicineGermline mutationInternal medicinemedicineskin and connective tissue diseasesCHEK2GeneCHEK2RAD51Cbusiness.industryOdds ratiomedicine.diseaseBRCA1lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBRCA2female genital diseases and pregnancy complications<i>BRCA1</i>030104 developmental biologyovarian cancerOncology030220 oncology & carcinogenesisPALB2recurrent mutationsRAD51C<i>PALB2</i>Ovarian cancerbusiness<i>RAD51C</i><i>BRCA2</i>Cancers
researchProduct

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives

2019

The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family memb…

0301 basic medicineOncologyGenetic testingendocrine system diseasesSettore MED/03 - GENETICA MEDICAMedical OncologyBiochemistrychemistry.chemical_compound0302 clinical medicineGermline mutationPARP inhibitorsTrabectedinSocieties MedicalOvarian Neoplasmsmedicine.diagnostic_testBRCA1 ProteinHematologyfemale genital diseases and pregnancy complicationsOncologyItaly030220 oncology & carcinogenesisFemalemedicine.drugHumanmedicine.medical_specialtyGenetic counselingOlaparib03 medical and health sciencesGeneticSomatic mutationsOvarian cancerMedicalInternal medicineBRCA1; BRCA2; Genetic testing; Germline mutations; Ovarian cancer; PARP inhibitors; Somatic mutations; BRCA1 Protein; BRCA2 Protein; Biochemistry; Female; Genetic Testing; Genetics; Humans; Italy; Medical Oncology; Ovarian Neoplasms; Germ-Line Mutation; Societies MedicalGeneticsmedicineGenetic predispositionHumansRucaparibGermline mutationsGerm-Line MutationGenetic testingBRCA2 Proteinbusiness.industrySomatic mutationOvarian NeoplasmCancermedicine.diseaseBRCA1BRCA2BRCA1; BRCA2; Genetic testing; Germline mutations; Ovarian cancer; PARP inhibitors; Somatic mutations030104 developmental biologyPARP inhibitorchemistrySocietiesOvarian cancerbusiness
researchProduct

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma

2021

BACKGROUND: Targeted genetic profiling of tissue samples is paramount to detect druggable genetic aberrations in patients with non-squamous non-small cell lung cancer (NSCLC). Accurate upfront estimation of tumor cell content (TCC) is a crucial pre-analytical step for reliable testing and to avoid false-negative results. As of now, TCC is usually estimated on hematoxylin-eosin (H&E) stained tissue sections by a pathologist, a methodology that may be prone to substantial intra- and interobserver variability. Here we the investigate suitability of digital pathology for TCC estimation in a clinical setting by evaluating the concordance between semi-automatic and conventional TCC quantification…

0301 basic medicineOncologymedicine.medical_specialtyConcordanceTumor cellsurologic and male genital diseases03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerneoplasmsLungbusiness.industryMolecular pathologyDigital pathologymedicine.diseasefemale genital diseases and pregnancy complicationsddc:030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisAdenocarcinomaOriginal ArticleSemi automaticbusiness
researchProduct

Detection of human papillomavirus DNA in formalin-fixed, paraffin-embedded squamous papillomas of the oral cavity

2018

Background Squamous papillomas are exophytic proliferations of surface oral epithelium. Human papillomavirus (HPV) infection is widely accepted as the etiology of squamous papillomas however the virus cannot be detected in a significant percentage of lesions. Material and methods Using polymerase chain reaction (PCR), we tested 35 formalin-fixed paraffin-embedded (FFPE) squamous papillomas for the presence of HPV DNA. Results Six papillomas (17%) tested positive for HPV DNA; four contained HPV-6 and two contained HPV-11. Given that β-globin DNA was only identified in half of the samples, DNA degradation appears to have significantly impacted the results. Conclusions The results likely repre…

0301 basic medicinePathologymedicine.medical_specialtyFormalin fixed paraffin embeddedOral cavityViruslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawHuman papillomavirus DNAmedicineGeneral DentistryPolymerase chain reactionOral Medicine and Pathologybusiness.industryResearchHPV infectionvirus diseases:CIENCIAS MÉDICAS [UNESCO]medicine.diseasefemale genital diseases and pregnancy complications030104 developmental biologychemistry030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASPapillomabusinessDNAJournal of Clinical and Experimental Dentistry
researchProduct

Prospective risk of stillbirth and neonatal complications in twin pregnancies: systematic review and meta-analysis

2016

Twin pregnancies are at increased risk of stillbirth. Uncomplicated twin pregnancies are commonly delivered earlier to prevent stillbirth; however, there is a risk of neonatal complications associated with being born prior to 39 weeks’ gestation. The optimal gestational age for delivery in twin pregnancies is unknown and likely varies by chorionicity. The present study aimed to determine the prospective risk of stillbirth in women with uncomplicated monochorionic and dichorionic twin pregnancies, and neonatal mortality risks, when delivered beyond 34 weeks of gestation. Data on twin pregnancies that reported rates of stillbirth were obtained from MEDLINE, EMBASE, and Cochrane Library. Separ…

0301 basic medicinePediatricsNeonatal intensive care unitPerinatal DeathCochrane LibraryInfant Newborn Diseases0302 clinical medicineObstetrics and gynaecologyPregnancyRisk FactorsTwins DizygoticMedicineProspective StudiesProspective cohort studyreproductive and urinary physiologyTwin Pregnancyhealth care economics and organizations030219 obstetrics & reproductive medicineObstetricsIncidence (epidemiology)Absolute risk reductionObstetrics and GynecologyGestational ageProspective riskGeneral MedicineStillbirthfemale genital diseases and pregnancy complicationsMeta-analysisGestationFemalemedicine.medical_specialtyeducationGestational AgeTwin-to-twin transfusion syndrome03 medical and health sciences030225 pediatricsJournal ArticleHumansGynecologyPregnancybusiness.industryResearchInfant NewbornTwins Monozygoticmedicine.diseaseConfidence interval030104 developmental biologyIntensive Care NeonatalPregnancy TwinbusinessBMJ (Clinical research ed.)
researchProduct

Postpartum listeria meningitis

2020

Highlights • Listeria monocytogenes is a rare cause of meningitis in immunocompetent patient. • Pregnancy and puerperium are accompanied by a decrease in cellular immunity. • Pregnancy and puerperium should be considered as risk factors for invasive listeriosis.

0301 basic medicinePediatricsmedicine.medical_specialty030106 microbiologyInfectious and parasitic diseasesRC109-216DiseaseAbortionmedicine.disease_causeAsymptomaticArticle03 medical and health sciences0302 clinical medicineImmune systemListeria monocytogenesmedicineMeningitis030212 general & internal medicinereproductive and urinary physiologyListeria monocytogenePregnancybusiness.industryPuerperiummedicine.diseaseAntimicrobialListeria monocytogenesfemale genital diseases and pregnancy complicationsMeningitiInfectious Diseasesmedicine.symptombusinessMeningitisIDCases
researchProduct